Coffee and Cardiovascular Health: Is There a Benefit?

Smart Ring Outperforms Apple Watch for Atrial Fibrillation Detection

News

Slideshow

ACC 2022

Consuming caffeine has been thought to induce cardiac dysrhythmias, leaving patients and physicians to worry that drinking coffee can worsen or trigger certain cardiovascular issues. However, findings from 3 new studies suggest consuming coffee on a daily basis can benefit persons with and without cardiovascular disease. The studies will be presented at the American College of Cardiology’s 71st Scientific Sessions, held April 2-4, 2022. In the slides below, find a brief preview of topline results that may inform clinical practice.

Related Content

April 21st 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

The CART ring was superior to the Apple Watch in automated AF detection with fewer unclassified ECGs, but neither device should serve as a definitive diagnostic tool.

August 30th 2023

Tirzepatide Improves Heart Failure Symptoms and Renal Function in People with Obesity, CKD

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

April 11th 2025

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

ACC 2025. Tirzepatide improved HF symptoms and renal function in patients with obesity-related HFpEF, regardless of CKD status, according to new findings from the SUMMIT trial.

Patient Care Editorial Staff

October 29th 2020

Research That Is Changing Endocrinology: Advances, Challenges, and The Future, with Irl B Hirsch, MD

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

Endocrinology in 2024: Advances, Challenges, and The Future, with Irl B Hirsch, MD

April 3rd 2025

ACC 2025: Cardiovascular Benefits of Semaglutide 2.4 mg Highlighted in Real-World Study

ACP 2025: Irl B Hirsch, MD, reviewed findings from 8 papers published in 2024 that he believes have made or will make a difference in the practice or understanding of the clinical area.

April 1st 2025

Smart Ring Outperforms Apple Watch for Atrial Fibrillation Detection

Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.

Related Content

April 21st 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

The CART ring was superior to the Apple Watch in automated AF detection with fewer unclassified ECGs, but neither device should serve as a definitive diagnostic tool.

August 30th 2023

Tirzepatide Improves Heart Failure Symptoms and Renal Function in People with Obesity, CKD

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

April 11th 2025

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

ACC 2025. Tirzepatide improved HF symptoms and renal function in patients with obesity-related HFpEF, regardless of CKD status, according to new findings from the SUMMIT trial.

Patient Care Editorial Staff

October 29th 2020

Research That Is Changing Endocrinology: Advances, Challenges, and The Future, with Irl B Hirsch, MD

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

April 3rd 2025

ACC 2025: Cardiovascular Benefits of Semaglutide 2.4 mg Highlighted in Real-World Study

ACP 2025: Irl B Hirsch, MD, reviewed findings from 8 papers published in 2024 that he believes have made or will make a difference in the practice or understanding of the clinical area.

April 1st 2025